MA45862A - Combinaison d'inhibiteurs du protéasome et d'anticorps anti-cd30 - Google Patents
Combinaison d'inhibiteurs du protéasome et d'anticorps anti-cd30Info
- Publication number
- MA45862A MA45862A MA045862A MA45862A MA45862A MA 45862 A MA45862 A MA 45862A MA 045862 A MA045862 A MA 045862A MA 45862 A MA45862 A MA 45862A MA 45862 A MA45862 A MA 45862A
- Authority
- MA
- Morocco
- Prior art keywords
- antibodies
- combination
- proteasome inhibitors
- proteasome
- inhibitors
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/22—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662370812P | 2016-08-04 | 2016-08-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA45862A true MA45862A (fr) | 2021-05-05 |
Family
ID=61074014
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA045862A MA45862A (fr) | 2016-08-04 | 2017-08-03 | Combinaison d'inhibiteurs du protéasome et d'anticorps anti-cd30 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20190192559A1 (fr) |
| EP (1) | EP3493793A4 (fr) |
| JP (1) | JP2019524780A (fr) |
| CN (1) | CN109562084A (fr) |
| CA (1) | CA3032011A1 (fr) |
| MA (1) | MA45862A (fr) |
| WO (1) | WO2018027022A1 (fr) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7652918B2 (ja) | 2021-03-01 | 2025-03-27 | ナントバイオ,インコーポレイテッド | 抗cd30モノクローナル抗体及びキメラ抗原受容体 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006039644A2 (fr) * | 2004-10-01 | 2006-04-13 | Medarex, Inc. | Procede pour traiter des lymphomes positifs cd30 |
| CA2727862C (fr) * | 2008-06-17 | 2016-04-19 | Millennium Pharmaceuticals, Inc. | Composes de borates esters et compositions pharmaceutiques contenant des composes |
| AU2011316917B2 (en) * | 2010-10-22 | 2016-02-25 | Seagen Inc. | Synergistic effects between auristatin-based antibody drug conjugates and inhibitors of the PI3K-AKT mTOR pathway |
| EP3076963A4 (fr) * | 2013-12-06 | 2017-09-13 | Millennium Pharmaceuticals, Inc. | Combinaison d'inhibiteurs de kinase aurora et d'anticorps anti-cd30 |
| TN2016000492A1 (en) * | 2014-05-20 | 2018-04-04 | Millennium Pharm Inc | Boron-containing proteasome inhibitors for use after primary cancer therapy. |
-
2017
- 2017-08-03 MA MA045862A patent/MA45862A/fr unknown
- 2017-08-03 CA CA3032011A patent/CA3032011A1/fr not_active Abandoned
- 2017-08-03 CN CN201780048484.9A patent/CN109562084A/zh active Pending
- 2017-08-03 US US16/322,244 patent/US20190192559A1/en not_active Abandoned
- 2017-08-03 JP JP2019505462A patent/JP2019524780A/ja active Pending
- 2017-08-03 EP EP17837675.2A patent/EP3493793A4/fr not_active Withdrawn
- 2017-08-03 WO PCT/US2017/045275 patent/WO2018027022A1/fr not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| US20190192559A1 (en) | 2019-06-27 |
| JP2019524780A (ja) | 2019-09-05 |
| CA3032011A1 (fr) | 2018-02-08 |
| EP3493793A4 (fr) | 2020-04-01 |
| EP3493793A1 (fr) | 2019-06-12 |
| CN109562084A (zh) | 2019-04-02 |
| WO2018027022A1 (fr) | 2018-02-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA50359A (fr) | Anticorps anti-cd38 et procédés d'utilisation | |
| MA42043A (fr) | Anticorps anti-ox40 et procédés d'utilisation de ceux-ci | |
| MA50956A (fr) | Anticorps anti-cd137 et procédés d'utilisation correspondants | |
| EP3581651A4 (fr) | Anticorps anti-gprc5d et molécule le contenant | |
| MA42925A (fr) | Anticorps anti-tigit et méthodes d'utilisation | |
| MA51552A (fr) | Anticorps anti-ox40 et procédés d'utilisation | |
| EP3618871A4 (fr) | Formulations d'anticorps anti-lag3 etco-formulations d'anticorps anti-lag3 et d'anticorps anti-pd-1 | |
| EP3626825A4 (fr) | Anticorps anti-cdh6 et conjugué anticorps anti-cdh6-médicament | |
| MA46525A (fr) | Anticorps anti-lag-3 et compositions | |
| MA50948A (fr) | Anticorps et procédés d'utilisation de ceux-ci | |
| MA44990A (fr) | Polythérapies d'inhibiteurs de hdac et d'inhibiteurs de pd-l1 | |
| EP3383914A4 (fr) | Anticorps anti-ox40 et leurs procédés d'utilisation | |
| MA45123A (fr) | Anticorps anti-tim-3 et leurs méthodes d'utilisation | |
| MA43018A (fr) | Anticorps anti-pd1 et procédés d'utilisation | |
| EP3472200A4 (fr) | Anticorps anti-myostatine et leurs procédés d'utilisation | |
| MA47849A (fr) | Anticorps anti-gitr et leurs procédés d'utilisation | |
| EP3525583A4 (fr) | Anticorps anti-c1s et leurs méthodes d'utilisation | |
| EP3436476A4 (fr) | Anticorps anti-ryk et leurs procédés d'utilisation | |
| EP3684819A4 (fr) | Anticorps anti-ykl40 et méthodes d'utilisation | |
| EP3408284A4 (fr) | Détection d'un anticorps dirigé contre un agent pathogène | |
| MA44391A (fr) | Combinaisons d'immunoconjugués anti-cd37 et d'anticorps anti-cd20 | |
| EP3842070A4 (fr) | Combinaison médicamenteuse de dérivé de quinoléine et d'anticorps | |
| EP3328429A4 (fr) | Peptides et anticorps pour l'élimination de biofilms | |
| EP3394098A4 (fr) | Anticorps anti-myostatine et procédés d'utilisation | |
| EP3710589A4 (fr) | Anticorps anti-c1s et procédés d'utilisation |